Gynecomastia as a Side Effect of Finasteride and Tamsulosin
Yes, gynecomastia is a documented side effect of finasteride, occurring in 0.3-2.2% of patients, while tamsulosin has emerging evidence suggesting a possible association, though this is less well-established.
Finasteride and Gynecomastia
The FDA drug label for finasteride clearly documents gynecomastia as an adverse effect 1. In the pivotal 4-year placebo-controlled study:
- Breast enlargement occurred in 0.5% (Year 1) and 1.8% (Years 2-4) of finasteride patients versus 0.1% and 1.1% in placebo
- Breast tenderness occurred in 0.4% (Year 1) and 0.7% (Years 2-4) versus 0.1% and 0.3% in placebo 1
In the MTOPS study examining combination therapy, gynecomastia rates were:
- Finasteride alone: 2.2%
- Tamsulosin alone: 1.1%
- Combination therapy: 1.5%
- Placebo: 0.7% 1
Mechanism and Clinical Considerations
Finasteride inhibits 5α-reductase, reducing dihydrotestosterone (DHT) levels, which alters the estrogen/androgen ratio and can trigger gynecomastia 2. This effect:
- Can occur with both high-dose (5 mg for BPH) and low-dose (1 mg for alopecia) formulations 3
- May persist even after drug discontinuation in some cases 3
- Can develop after short-term use (as brief as 1 month) 3
Critical pitfall: Gynecomastia from low-dose finasteride (1 mg for alopecia) appears significantly underreported, with only 8 cases documented since 1997 approval, suggesting inadequate patient counseling 3.
Tamsulosin and Gynecomastia
The evidence for tamsulosin-associated gynecomastia is more limited but emerging:
The FDA label for tamsulosin does not list gynecomastia as a direct adverse effect, though it notes increased mammary gland tumors in rodent studies secondary to hyperprolactinemia 4. However:
- A pharmacovigilance analysis identified tamsulosin as having the highest signal for gynecomastia among α1-adrenergic receptor antagonists (Information Component 95% = 2.43 in VigiBase) 5
- This represents a potential new safety signal not previously described 5
- In the large PEM study of 12,484 patients, gynecomastia was not specifically highlighted as a common adverse effect 6
Combination Therapy
When finasteride and tamsulosin are used together:
- The gynecomastia rate (1.5%) falls between monotherapy rates
- The combination does not appear to have additive effects on gynecomastia risk 1
- Finasteride is the primary driver of gynecomastia risk in combination therapy 7
Clinical Recommendations
Before prescribing finasteride: Counsel patients explicitly about gynecomastia risk (approximately 1-2%), emphasizing that:
- It can occur with any dose
- It may persist after discontinuation
- Early intervention upon first signs may prevent irreversible fibrosis 3
For tamsulosin: While the absolute risk appears lower and less established, be aware of the emerging pharmacovigilance signal, particularly in patients with other risk factors for gynecomastia 5.
If gynecomastia develops: Consider drug discontinuation, though regression may be incomplete. Selective estrogen receptor modulators (e.g., raloxifene) or surgical intervention may be necessary for persistent cases 3.